7 completed. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Troglitazone: new trials by email Literature Review of Troglitazone trials Research Report on Troglitazone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Incretin-based Drugs and the Risk of Heart Failure DPP-4 inhibitors, GLP-1 analogs, Insulins - Type 2 Diabetes Mellitus | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1499650 | 2014-03-01 | 2016-04-19 | |
| Incretin-based Drugs and Acute Pancreatitis DPP-4 inhibitors, GLP-1 analogs, Insulins - Diabetes Mellitus, Type 2 | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1417914 | 2014-03-01 | 2016-11-03 | |
| Incretin-based Drugs and Pancreatic Cancer DPP-4 inhibitors, GLP-1 analogs, Sulfonylureas - Diabetes Mellitus, Type 2 | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 886172 | 2014-03-01 | 2016-03-14 | |
| To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies Canakinumab 150 mg, Placebo to Canakinumab - Type 2 Diabetes Mellitus, Impaired Glucose Tolerance | Phase 2 | Completed | Novartis | 246 | 2010-02-01 | 2011-09-05 |
| Fracture Risk With Thiazolidinediones TZD only (RSG or PIO or troglitazone), TZD + spironolactone, TZD + amiloride - Fractures, Bone, Type II Diabetes | Completed | GlaxoSmithKline | 98483 | 2009-05-01 | 2017-05-30 | |
| Troglitazone in Treating Patients With Liposarcoma troglitazone - Sarcoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 85 | 1997-06-01 | 2017-02-13 |
| TART - Troglitazone Atherosclerosis Regression Trial troglitazone - Atherosclerosis, Diabetes Mellitus | Phase 2 / Phase 3 | Completed | Parke-Davis | 288 | 1997-01-01 | 2009-12-11 |
Diabetes Mellitus, Type 2 (5) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Fractures, Bone (1) · Glucose Intolerance (1) · Heart Failure (1) · Insulin Resistance (1) · Liposarcoma (1) · Metabolic Syndrome (1) · Pancreatic Neoplasms (1) · Pancreatitis (1) · Sarcoma (1)
Canadian Network for Observational Drug Effect Studies, CNODES (3) · Dana-Farber Cancer Institute (1) · GlaxoSmithKline (1) · Novartis (1) · Parke-Davis (1)
Canada (4) · United States (3) · Australia (1) · Finland (1) · Germany (1) · India (1) · Italy (1)
Pierre Ernst, MD, MSc (3) · George D. Demetri, MD (1) · Howard N. Hodis, MD (1)
PMID 10097144, PMID 26888382, PMID 27007958, PMID 27479930
P30CA006516 (1)